REDUCTION OF TUMOR NECROSIS FACTOR-ALPHA AND INTERFERON-GAMMA CONCENTRATION ON TUBERCULOSIS WITH DIABETES MELLITUS AS A MARKER IN DECREASE IMMUNE SYSTEM

  • NELLY MARISSA Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.
  • NUR RAMADHAN Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.
  • SARI HANUM Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.
  • MARLINDA Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.
  • EKA FITRIA Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.
  • ABIDAH NUR Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh Besar, Indonesia.

Abstract

Objective: This study aimed to determine the decreased immune response of tuberculosis (TB) with diabetes mellitus (DM) patients.


Methods: A total of 105 TB patients who were undergoing treatment at health centers and hospitals in Banda Aceh and Aceh Besar were included in this study. Data collection was carried out by interviewed to obtained demographic and respondent categories based on the diagnosis. Measurements of height and weight were also conducted to obtain body mass index data. 5 mL peripheral blood was taken from each respondent group into a TB with DM (TB+DM) and TB without DM (TB-DM). The blood tested usage tumor necrosis factor-alpha (TNF-α) level using enzyme-linked immunosorbent assay and interferon-gamma (IFN-γ) using IFN-γ release assay.


Results: The average concentration of both TNF-α and IFN-γ was higher in TB-DM group (TNF-a 5.2 pg/mL; IFN-g 1.5 IU/mL) than in TB+DM group (TNF-a 2.06 pg/mL; IFN-g 2.86 IU/mL). There were significant differences in TNF-α between the two groups but no significant differences in IFN-γ protein concentration.


Conclusion: The immune response of TB patients with DM symptoms was markedly reduced by the decreased expression of TNF-α and IFN-γ.

Keywords: Tuberculosis, Diabetes mellitus, Tumor necrosis factor-alpha, Interferon-gamma

References

1. Badan Penelitian dan Pengembangan Kesehatan. Laporan Nasional Riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan; 2019. p. 1-674.
2. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of Type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007;45:428-35.
3. Lachmandas E, Vrieling F, Wilson LG, Joosten SA, Netea MG, Ottenhoff TH, et al. The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis. PLoS One 2015;10:1-13.
4. Meenakshi P, Ramya S, Lavanya J, Vijayalakshmi V, Sumanlatha G. Effect of IFN-?, IL-12 and IL-10 cytokine production and mRNA expression in tuberculosis patients with diabetes mellitus and their household contacts. Cytokine 2016;81:127-36.
5. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, et al. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic Type 1, Type 17, and other proinflammatory cytokines. Ann Am Thorac Soc 2013;10:441-9.
6. Zin NM, Hanafiah A, Masod NH. Infeksi Mycobacterium tuberculosis : Data demografi dan perbandingan ujian kerentanan anti-tuberkulosis. J Sains Malays 2018;47:543-9.
7. Fahmi MA. Prevalensi diabetes mellitus tipe 2 pada pasien tuberkulosis di kabupaten temanggung jawa tengah. J Wiyata 2016;3:168-73.
8. Harso AD, Syarif AK, Arlinda D, Indah RM, Yulianto A, Yudhistira A, et al. Perbedaan faktor sosiodemografi dan status gizi pasien tuberkulosis dengan dan tanpa diabetes berdasarkan registri Tuberkulosis-Diabetes Melitus 2014. J Media Litbangkes 2017;27:65-70.
9. Illahi RK, Pramestutie HR, Shandra M, Desyana DW. The use of assistive counselling toll “Lung TB Care” to increase patient’s knowledge level (a study in tuberculosis patients at Malang’s primary health care centers). Int J Pharm Pharm Sci 2018;10:2-5.
10. Arlinda D, Yulianto A, Syarif AK, Harso AD, Indah RM, Karyana M. Pengaruh diabetes melitus terhadap gambaran klinis dan keberhasilan pengobatan tuberkulosis di tujuh RSU kelas A dan B di jawa dan bali. J Media Litbangkes 2017;27:31-8.
11. Hayashi S, Chandramohan D. Risk of active tuberculosis among people with diabetes mellitus: Systematic review and meta-analysis. Trop Med Int Health 2018;23:1058-70.
12. Cavalcanti YV, Brelaz MC, Neves JK, Ferraz JC, Pereira VR. Role of TNF-alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis. Pulm Med 2012;2012:745483.
13. Saranya P, Parthasarathy V, Hariprasad B, Rani HS. Effect of diabetes mellitus on rifampicin peak serum concentration. Int J Pharm Pharm Sci 2016;8:8-11.
14. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014;44:617-26.
15. Cheekatla SS, Tripathi D, Venkatasubramanian S, Nathella PK, Paidipally P, Ishibashi M, et al. NK-CD11c+ cell crosstalk in diabetes enhances IL-6-mediated inflammation during Mycobacterium tuberculosis infection. PLoS Pathog 2016;12:e1005972.
16. Raposo-García S, Guerra-Laso JM, García-García S, Juan-García J, López-Fidalgo E, Diez-Tascón C, et al. Immunological response to Mycobacterium tuberculosis infection in blood from Type 2 diabetes patients. Immunol Lett 2017;186:41-5.
17. Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S, et al. Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis. Immunology 2015;144:677-86.
18. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract 2014;106:191-9.
Statistics
57 Views | 12 Downloads
Citatons
How to Cite
NELLY MARISSA, NUR RAMADHAN, SARI HANUM, MARLINDA, EKA FITRIA, and ABIDAH NUR. “REDUCTION OF TUMOR NECROSIS FACTOR-ALPHA AND INTERFERON-GAMMA CONCENTRATION ON TUBERCULOSIS WITH DIABETES MELLITUS AS A MARKER IN DECREASE IMMUNE SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 11, Oct. 2019, pp. 151-4, doi:10.22159/ajpcr.2019.v12i11.35424.
Section
Original Article(s)